Issue Date | Title | Author(s) |
2014 | Addition of aprepitant improves protection against cisplatin-induced emesis when a conventional anti-emetic regimen fails | Hu, Weiheng; Fang, Jian; Nie, Jun; Dai, Ling; Chen, Xiaoling; Zhang, Jie; Ma, Xiangjuan; Tian, Guangming; Han, Jindi |
2015 | Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics | Zhang, Jie; Gao, Jing; Li, Yanyan; Nie, Jun; Dai, Ling; Hu, Weiheng; Chen, Xiaoling; Han, Jindi; Ma, Xiangjuan; Tian, Guangming; Wu, Di; Shen, Lin; Fang, Jian |
2016 | Clinical characteristics associated with non-small-cell lung cancer harboring ALK rearrangements in Chinese patients | Tian, Guangming; Zhao, Xinliang; Nie, Jun; Dai, Ling; Hu, Weiheng; Zhang, Jie; Chen, Xiaoling; Han, Jindi; Ma, Xiangjuan; Wu, Di; Han, Sen; Long, Jieran; Wang, Yang; Fang, Jian |
2015 | Dynamic changes of circulating tumor cells during chemotherapy as a prognostic factor in patients with advanced lung cancer | Zhang, Jie; Fang, Jian; Nie, Jun; Dai, Ling; Hu, Weiheng; Chen, Xiaoling; Han, Jindi; Ma, Xiangjuan; Tian, Guangming; Wu, Di |
2015 | Dynamic changes of circulating tumor cells during chemotherapy as a prognostic factor in patients with advanced lung cancer | Zhang, Jie; Fang, Jian; Nie, Jun; Dai, Ling; Hu, Weiheng; Chen, Xiaoling; Han, Jindi; Ma, Xiangjuan; Tian, Guangming; Wu, Di |
2016 | Efficacy and safety of extended use of platinum-based doublet chemotherapy plus endostatin in patients with advanced nonsmall cell lung cancer | Hu, Weiheng; Fang, Jian; Nie, Jun; Dai, Ling; Zhang, Jie; Chen, Xiaoling; Ma, Xiangjuan; Tian, Guangming; Wu, Di; Han, Sen; Han, Jindi; Wang, Yang; Long, Jieran |
2019 | Efficacy and toxicities of gemcitabine and cisplatin combined with endostar in advanced thymoma and thymic carcinoma | Wang, Yang; Nie, Jun; Dai, Ling; Hu, Weiheng; Chen, Xiaoling; Han, Jindi; Ma, Xiangjuan; Tian, Guangming; Han, Sen; Long, Jieran; Zhang, Ziran; Fang, Jian |
Jun-2021 | Evaluation of efficacy and toxicity of nivolumab combined with or without docetaxel in patients with advanced NSCLC | Wang, Yang; Nie, Jun; Dai, Ling; Hu, Weiheng; Zhang, Jie; Chen, Xiaoling; Ma, Xiangjuan; Tian, Guangming; Han, Jindi; Han, Sen; Wu, Di; Long, Jieran; Zhang, Ziran; Fang, Jian |
5-Mar-2021 | Immune-Related Adverse Events and Their Association With the Effectiveness of PD-1/PD-L1 Inhibitors in Non-Small Cell Lung Cancer: A Real-World Study From China | Chen, Xiaoling; Nie, Jun; Dai, Ling; Hu, Weiheng; Zhang, Jie; Han, Jindi; Ma, Xiangjuan; Tian, Guangming; Han, Sen; Wu, Di; Wang, Yang; Long, Jieran; Zhang, Ziran; Fang, Jian |
Jun-2022 | The overall survival benefit in Chinese ALK(+) NSCLC patients received targeted therapies | Tian, Guangming; Zhao, Xinliang; Nie, Jun; Dai, Ling; Hu, Weiheng; Zhang, Jie; Chen, Xiaoling; Han, Jindi; Ma, Xiangjuan; Wu, Di; Han, Sen; Long, Jieran; Wang, Yang; Zhang, Ziran; Fang, Jian |
Jun-2020 | A phaseIIstudy of anlotinib in 45 patients with relapsed small cell lung cancer | Wu, Di; Nie, Jun; Hu, Weiheng; Dai, Ling; Zhang, Jie; Chen, Xiaoling; Ma, Xiangjuan; Tian, Guangming; Han, Jindi; Han, Sen; Long, Jieran; Wang, Yang; Zhang, Ziran; Fang, Jian |
May-2021 | Prognostic factor analysis of patients with small cell lung cancer: Real-world data from 988 patients | Ma, Xiangjuan; Zhang, Ziran; Chen, Xiaoling; Zhang, Jie; Nie, Jun; Da, Ling; Hu, Weiheng; Tian, Guangming; Wu, Di; Han, Jindi; Han, Sen; Long, Jieran; Wang, Yang; Fang, Jian |
2014 | Retrospective study of surgery versus non-surgical management in limited-disease small cell lung cancer | Zhang, Jie; Li, Shaolei; Chen, Xiaoling; Han, Jindi; Nie, Jun; Dai, Ling; Hu, Weiheng; Tian, Guangming; Ma, Xiangjuan; Han, Sen; Wu, Di; Zheng, Qingfeng; Yang, Yue; Fang, Jian |
2019 | Salvage treatment with anlotinib for advanced non-small cell lung cancer | Wu, Di; Nie, Jun; Dai, Ling; Hu, Weiheng; Zhang, Jie; Chen, Xiaoling; Ma, Xiangjuan; Tian, Guangming; Han, Jindi; Han, Sen; Long, Jieran; Wang, Yang; Zhang, Ziran; Fang, Jian |